We focused on the assessment of CTC heterogeneity in invasive-breast-cancer patients and the study of its stemlike features by the simultaneous usage of three markers (CD44 and CD24, ALDH1, or CD133), depending on N-cadherin expression. This evidence concerns the gene CD44 and breast carcinoma.